Immatics N.V.(IMTX) - 2025 Q4 - Annual Report

Financial Performance and Losses - As of December 31, 2025, the company had accumulated consolidated losses of €786.0 million and expects to continue incurring significant operating losses in the foreseeable future[32]. - The company has German federal net operating loss carryforwards of €204.7 million and U.S. federal net operating loss carryforwards of €288.8 million for the year ended December 31, 2025[40]. - The company has no products approved for commercial sale and has not generated revenue from product sales, indicating a reliance on future product development for financial viability[32]. - The company anticipates needing additional capital to fund operations and execute its business plan, with no committed external sources of funds currently available[36]. Clinical Trials and Product Development - Clinical trials are expected to be expensive and time-consuming, with costs potentially higher than conventional therapeutic technologies due to the complexity of the company's product candidates[44]. - The company may face delays in clinical trials due to various factors, including regulatory approvals and patient recruitment challenges, which could increase costs and delay product development[42]. - The company relies on third parties for conducting clinical trials and manufacturing, which introduces risks that could impair the advancement and commercialization of its product candidates[38]. - There is no assurance regarding the outcomes of ongoing or planned clinical trials, and results from earlier-stage trials are particularly unpredictable[53]. - Certain clinical trials utilize an "open-label, single arm" design, which may introduce selection bias and affect the safety and efficacy data[54]. - Results from preclinical studies and early-stage clinical trials may not predict outcomes in later-stage trials, and variability in results is expected for patient-specific therapies[55]. - Preliminary interim data from clinical trials may not be indicative of final results, and such data should be viewed with caution until fully evaluated[56]. Regulatory and Compliance Risks - Regulatory authorities may require additional studies or trials before granting approval, which could delay commercialization and increase costs[59]. - The approval process varies by jurisdiction, and failure to comply with regulatory requirements could limit market potential[63]. - The company faces risks related to the approval of product candidates developed in combination with other therapies, which may affect market success[61]. - Clinical trials conducted outside the United States may not be accepted by the FDA, potentially leading to additional costly trials[72]. - The FDA has increased scrutiny on the accelerated approval pathway, requiring confirmatory studies to be conducted diligently[75]. - The company must navigate stringent obligations under the GDPR and other data protection laws, which could restrict its operations and lead to enforcement actions[181]. Manufacturing and Supply Chain Challenges - Manufacturing of cellular products is complex and costly, with higher production costs compared to traditional small molecule drugs[87]. - The company must maintain a chain of identity for patient-specific cellular products, which is complex and critical for regulatory compliance[89]. - The company faces risks related to manufacturing issues, including contamination and variability in patient starting material, which could delay product availability[88]. - The manufacturing strategy includes using Contract Manufacturing Organizations (CMOs) for various processes, including cGMP manufacturing, which may impact clinical advancement and commercialization[113]. - Manufacturing challenges, including production costs and quality control, could delay regulatory approval and impair the ability to manufacture commercial quantities at acceptable costs[95]. Intellectual Property and Legal Risks - The company is dependent on intellectual property licensed from third parties, and termination of these licenses could harm its business[123]. - The patent protection for the company's product candidates is uncertain, and failure to maintain adequate protection could allow competitors to develop similar products[125]. - The company may face litigation regarding intellectual property rights, which could adversely affect operations and require substantial damages if found infringing[131]. - Compliance with patent maintenance requirements is crucial; non-compliance could lead to loss of patent rights and allow competitors to enter the market[136]. - The outcome of patent litigation is unpredictable, and adverse results could have a material adverse effect on the company's stock price[135]. Market and Competitive Landscape - The company faces substantial competition in the biopharmaceutical sector, which may impact its ability to successfully develop and commercialize its products[38]. - The biotechnology industry is characterized by rapid technological advancements and intense competition, with larger competitors having significantly greater financial resources[168]. - The company anticipates increased competition as more companies enter the market and scientific developments in cancer therapies accelerate[170]. - Market acceptance of product candidates is crucial, and failure to gain sufficient acceptance could result in inadequate product revenues[103]. Governance and Shareholder Rights - The company may be subject to the Dutch large company regime, affecting governance structure and board appointments if certain criteria are met[211]. - The influence of principal shareholders on board decisions could delay or prevent changes in corporate control, potentially affecting shareholder interests[205]. - Shareholders must consult the Board before exercising rights to put items on the agenda for general meetings, which can delay strategic changes[221]. - The company's governance structure may impair shareholders' ability to benefit from a change in control, potentially affecting market prices[222]. Operational and External Risks - Health epidemics and natural disasters could disrupt operations and adversely affect financial results, highlighting the need for risk management strategies[162]. - Cybersecurity threats are increasing, and breaches could lead to significant monetary losses and disruptions in product development programs[190][191]. - The company faces significant risks including decreased demand for product candidates, potential litigation costs, and reputational damage, which could adversely affect financial performance[194]. - The company is highly dependent on key personnel, including its Chief Executive Officer and other executive officers, which poses a risk to its business strategy if these individuals leave[165].